EUVIMEDEUVIMED entdecken
Crossref

First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe

Jihye Han, Aaron S Kesselheim

Health Affairs · 2025

DOI: 10.1377/hlthaff.2024.01072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs, 2025. Verfasst von Jihye Han und 1 weiteren Autor:innen. Beteiligte Einrichtung: Jihye Han (jihan@bwh.harvard.edu), Brigham and Women's Hospital and Harvard University, Boston, Massachusetts. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Arnold Ventures and the Commonwealth Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalUnited StatesUnited States Food and Drug AdministrationEuropeHumansClinical Trials as Topic

Autor:innen und Institutionen

  • Jihye Han (jihan@bwh.harvard.edu), Brigham and Women's Hospital and Harvard University, Boston, Massachusetts.
  • Aaron S. Kesselheim, Brigham and Women's Hospital and Harvard University.

Förderung

  • Arnold Ventures and the Commonwealth Fund

Zitieren

APA

Han, J., & Kesselheim, A. S. (2025). First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe. Health Affairs. https://doi.org/10.1377/hlthaff.2024.01072

Vancouver

Han J, Kesselheim AS. First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe. Health Affairs. 2025. doi:10.1377/hlthaff.2024.01072

BibTeX
@article{Han2025,
  author = {Han, Jihye and Kesselheim, Aaron S},
  title = {First-In-Class Drugs Experienced Different Regulatory Treatment In The US And Europe},
  journal = {Health Affairs},
  year = {2025},
  doi = {10.1377/hlthaff.2024.01072}
}
Kostenlos starten →